1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66F29AA7760794E2B65258384001C1DC9
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-competitive-intelligence-landscape-assessment-differentiated-service-levels-technology-enablement-artificial-intelligence?opendocument
18
19opendocument
2018.212.83.37
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Competitive and Business Intelligence Structure and Alignment

Competitive Intelligence Landscape Assessment: Differentiated Service Levels, Technology Enablement and Artificial Intelligence

ID: 5544


Features:

26 Info Graphics

2 Data Graphics

22 Metrics

1 Narratives


Pages/Slides: 35


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Competitive Intelligence Landscape Assessment: Differentiated Service Levels, Technology Enablement and Artificial Intelligence”

STUDY OVERVIEW

Aided by technological advances, Competitive Intelligence systems are now able to more rapidly deliver critical business insights that lead to quicker business decisions. However, the challenge for many organizations is leveraging emerging technologies, artificial intelligence and machine learning systems effectively to accelerate and enhance the productivity of the competitive intelligence function.


Best Practices, LLC conducted this landscape assessment using a meta-analysis approach to identify evolutionary insights for Competitive Intelligence service levels, technology enablement and artificial intelligence in the biopharmaceutical industry. Insights in this research have been distilled from 10 of Best Practices, LLC’s existing benchmarking studies on the CI function.

KEY TOPICS

  • Competitive intelligence standards of excellence for project support
  • Competitive intelligence differentiated service levels
  • Competitive intelligence process excellence
  • Competitive intelligence technology enablement and solutions
  • Emerging artificial intelligence, automation, and machine learning systems that support competitive intelligence

KEY METRICS
  • Most effective primary, secondary and internet sources for competitive intelligence
  • Budget allocation for competitive intelligence software, tools and databases

SAMPLE KEY FINDINGS
  • Overlaying a Code of Ethics Across the Entire Competitive Intelligence Process: When crafting the competitive intelligence function’s ethical code of conduct, partner with legal department to ensure that all relevant laws and regulations have been interpreted correctly. This partnership will give the legal department insight into the competitive intelligence process, accelerating future responses to legal and ethical uncertainty.
  • Competitive Intelligence Technologies: Many tools and technologies are employed across the competitive intelligence / knowledge ecosystem – without any single vendor gaining dominant share.

METHODOLOGY

Best Practices, LLC captured data from 10 of its benchmarking studies to conduct a Competitive Intelligence Landscape Assessment for the biopharmaceutical sector.


Industries Profiled:
Medical Device; Pharmaceutical; Health Care; Diagnostic; Manufacturing; Biotech; Biopharmaceutical; Technology; Communications; Consumer Products; Banking; Financial Services; Insurance; Research; Marketing; Chemical; High Tech; Consulting; Service; Electronics; Internet; Distribution; Computer Software; Energy; Clinical Research; Laboratories; Computers; Utilities; Telecommunications; Engineering; Shipping; Professional Services; Logistics; Science


Companies Profiled:
3M Pharmaceuticals; Abbott; Abbott Nutrition; Abbott Laboratories; AbbVie; actavis; Aditya Birla Group; Adocia; Alcon; Alcon Laboratories; Alembic; Alkermes; Allergan; Alnylam Pharmaceuticals; Amgen; Amylin; Anoto; ApotheCom; ARIAD; Array BioPharma; Astellas; AstraZeneca; B.Braun; Bausch & Lomb; Baxter Healthcare; Baxter International; Bayer Healthcare; Bayer; Biocon; BioCryst Pharmaceuticals; Biogen; Biogen Idec; Biological E. Limited; BioMarin; Biovail; Bioventus; Boehringer Ingelheim; Bristol-Myers Squibb; Cadila Pharmaceuticals; Centocor; Inc.; Central Bank of India; Citibank; Colorcon; ConjuChem Biotechnologies; Covance; Covidien; CSL Behring; Cubist Pharmaceuticals; Daiichi Sankyo; Datamatics Financial Services; Dendreon Corporation; Dentsply International; Diners Club International; doTerra; Dr Reddy's Laboratories; Eisai; Eli Lilly and Company; EMD Serono; Emergent BioSolutions; Endo Pharmaceuticals; Essilor International S.A.; Ethicon Endo-Surgery Inc.; Ethicon; Johnson & Johnson; Ethos Health Communications; Farma Health; Ferring Pharmaceuticals; Genentech; GlaxoSmithKline ; Gilead Sciences; Glenmark; Grifols; Human Genome Sciences; IBM; Immunex; IMS Health; Indegene Lifesystems; Infosys; Inspire Pharmaceuticals; Intel; Intermountain Healthcare; Ipsen; Ironwood; Janssen; Jazz Pharmaceuticals; King Pharmaceuticals; Kodak; Lac Mac; Lilly; Lonza Inc.; Mallinckrodt; McKesson; MedImmune; Medtronic; Medrad; Merck; Merck Serono; MyDataBall; Novartis; Nova Nordisk; Oracle; Orion Pharmaceuticals; PDL; PDL BioPharma; Pfizer; Pharma Consulting; Phillips; Procter & Gamble Pharma; Progress Energy; ProStrakan; Purdue Pharma; Quintiles; Ranbaxy; Roche; Rxperts; Salt Creek Biosciences; Sanofi; Sanofi Pasteur; Sanofi-Aventis; Santen; SAS; Sequor; Shire; Stiefel; Sunovion; Syntel; Takeda Pharmaceuticals; Tata Technologies; Teleflex; Tesaro; Teva Pharmaceutical Industries Ltd; Theratechnologies; Torrent Pharmaceuticals Ltd.; Transform Strategy Partners; UCB Pharma; UPS; Upsher-Smith; Vertex Pharmaceuticals; Vifor Pharma; Vivus; VMware; Waters; Waters Corporation; Women's Choice Pharmaceuticals; Wyeth Nutrition/Nestle; Xanodyne Pharmaceuticals; Zydus


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.